デノスマブの世界市場レポート 2025

デノスマブ市場規模は、今後数年で急成長が見込まれます。2029年にはCAGR10.9％で55億9,000万米ドルに成長します。予測期間の成長は、骨転移の発生率の上昇、がん治療の進歩、骨粗鬆症の流行、骨粗鬆症に対する意識の高まり、新たな適応症に対する規制当局の承認などに起因すると考えられます。予測期間における主な動向としては、戦略的提携やパートナーシップ、デジタルヘルスソリューションとの統合、適応症や臨床応用の拡大、バイオシミラー開発の進展などが挙げられます。

骨粗鬆症の有病率の増加は、今後のデノスマブ市場の拡大を牽引すると予想されます。骨粗鬆症は、骨がもろくなることで骨密度が低下し、骨折のリスクが高まる疾患です。デノスマブは、RANKリガンドを標的として骨吸収を抑制することで骨粗鬆症を治療します。例えば、2023年9月、米国の政府機関である国立生物工学情報センター（NCBI）は、カナダ加齢縦断研究（Canadian Longitudinal Study on Aging）のデータから、地域在住の高齢者における女性の医師診断による骨粗鬆症の有病率は12.7％、DXAで確認された骨粗鬆症の有病率は5.9％であったと報告しました。さらに、Buttrosらによる横断研究では、40歳から75歳の閉経後女性において、骨密度（BMD）測定により診断された骨粗鬆症の有病率は24.6％でした。その結果、骨粗鬆症の有病率の増加がデノスマブ市場の成長に拍車をかけています。

デノスマブ市場の主要プレーヤーは、競争優位性を獲得するために、革新的なソリューション、特に骨粗鬆症の第一選択治療を導入する努力を強めています。骨粗鬆症の第一選択治療とは、骨粗鬆症と診断された患者を管理するためにヘルスケア専門医が推奨する最初の治療法を指します。例えば、2022年11月、中国のバイオテクノロジー企業であるBoan Biotechは、デノスマブのバイオシミラーであるBoyoubeiの承認を中国国家医薬品監督管理局（NMPA）から取得し、デノスマブ注射剤を開発した初の中国企業となりました。また、Boyoubeiは、世界なマーケティング戦略により、欧米を含む中国以外の市場にも導入される予定です。様々な治療ガイドラインにおいて骨粗鬆症の第一選択薬として位置づけられているBoyoubeiは、骨粗鬆症患者の股関節骨折、非椎体骨折、椎体骨折のリスクを大幅に減少させることが期待されています。特筆すべきは、BoyoubeiがProlia（デノスマブのオリジネーター）のバイオシミラーとして世界で初めて製造販売承認を取得したことです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、コロナ、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界デノスマブ PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界のデノスマブ市場：成長率分析
• 世界のデノスマブ市場の実績：規模と成長, 2019-2024
• 世界のデノスマブ市場の予測：規模と成長, 2024-2029, 2034F
• 世界デノスマブ総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のデノスマブ市場薬物分類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• プロリア
• シュゲヴァ
• その他
• 世界のデノスマブ市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 60mg
• 120mg
• 世界のデノスマブ市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• ホームケア
• 専門クリニック
• 外来手術センター

第7章 地域別・国別分析

• 世界のデノスマブ市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のデノスマブ市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• デノスマブ市場：競合情勢
• デノスマブ市場：企業プロファイル
  • Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Novartis International AG Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
  • GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Eli Lilly and Company
• Amgen Inc.
• Asahi Kasei Corporation
• Teva Pharmaceutical Industries Ltd.
• Astellas Pharma Inc.
• Daiichi Sankyo Company, Limited
• Mylan N.V.
• Sandoz International GmbH
• Daiichi Sankyo Company Limited
• Aurobindo Pharma Limited
• Cipla Limited
• Dr. Reddy's Laboratories Ltd.
• Hikma Pharmaceuticals PLC
• Celltrion Inc.
• Amneal Pharmaceuticals Inc

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• デノスマブ市場2029：新たな機会を提供する国
• デノスマブ市場2029：新たな機会を提供するセグメント
• デノスマブ市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Denosumab is a monoclonal antibody employed in the treatment of bone-related conditions, particularly osteoporosis and bone metastases. Its mechanism of action involves inhibiting osteoclast formation, reducing bone resorption, increasing bone mineral density, and consequently lowering the risk of fractures.

The main classifications of denosumab drugs include Prolia, Xgeva, and others. Prolia is a prescription medicine specifically used for treating osteoporosis in postmenopausal women who are at a high risk of fractures or cannot use another osteoporosis medication. This drug is available in 60 mg and 120 mg doses and is utilized by various end-users such as hospitals, home care services, specialty clinics, and ambulatory surgical centers.

The denosumab market research report is one of a series of new reports from The Business Research Company that provides denosumab market statistics, including denosumab industry global market size, regional shares, competitors with a denosumab market share, detailed denosumab market segments, market trends and opportunities, and any further data you may need to thrive in the denosumab industry. This denosumab market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The denosumab market size has grown rapidly in recent years. It will grow from $3.27 billion in 2024 to $3.7 billion in 2025 at a compound annual growth rate (CAGR) of 13.1%. The growth in the historic period can be attributed to clinical trials and research advancements, FDA approvals and regulatory milestones, growing awareness of bone health, strategic partnerships and marketing initiatives.

The denosumab market size is expected to see rapid growth in the next few years. It will grow to $5.59 billion in 2029 at a compound annual growth rate (CAGR) of 10.9%. The growth in the forecast period can be attributed to rising incidence of bone metastases, advancements in cancer therapies, osteoporosis prevalence, increased awareness of osteoporosis, regulatory approvals for new indications. Major trends in the forecast period include strategic collaborations and partnerships, integration with digital health solutions, expanded indications and clinical applications, advancements in biosimilar development.

The growing prevalence of osteoporosis is expected to drive the expansion of the denosumab market in the future. Osteoporosis is a condition in which bones become fragile, leading to reduced bone density and an increased risk of fractures. Denosumab treats osteoporosis by inhibiting bone resorption through targeting the RANK ligand. For example, in September 2023, the National Center for Biotechnology Information (NCBI), a US-based government agency, reported that data from the Canadian Longitudinal Study on Aging showed a 12.7% prevalence of physician-diagnosed osteoporosis and a 5.9% rate of DXA-confirmed osteoporosis in females among older adults living in the community. Additionally, a cross-sectional study by Buttros and colleagues found a 24.6% prevalence of osteoporosis in postmenopausal women aged 40 to 75, diagnosed using bone mineral density (BMD) measurements. As a result, the increasing prevalence of osteoporosis is fueling the growth of the denosumab market.

Key players within the denosumab market are intensifying their efforts to introduce innovative solutions, particularly first-line treatments for osteoporosis, to gain a competitive advantage. First-line treatment for osteoporosis denotes the initial therapeutic approach recommended by healthcare practitioners for managing individuals diagnosed with the condition. For instance, in November 2022, Boan Biotech, a China-based biotechnology firm, secured approval from China's National Medical Products Administration (NMPA) for its denosumab biosimilar, Boyoubei, becoming the first Chinese company to develop a denosumab injection. Boyoubei is also slated for introduction into markets beyond China, including Europe and the United States, with a global marketing strategy in place. Positioned as a first-line treatment option for osteoporosis in various treatment guidelines, Boyoubei holds promise in significantly reducing the risk of hip, non-vertebral, and vertebral fractures among affected individuals. Notably, Boyoubei stands out as the world's first biosimilar to Prolia (the originator of denosumab) to receive marketing approval.

In June 2022, Organon, a pharmaceutical company headquartered in the United States, entered into a partnership with Henlius to commercialize Henlius for an undisclosed sum. This collaboration enables Organon to obtain the commercialization rights for biosimilar candidates referencing Perjeta (Pertuzumab, HLX11) and Prolia or Xgeva (Denosumab). The agreement aligns with Organon's expertise in biosimilar commercialization and its dedication to providing high-quality and cost-effective biologic medicines globally, with a specific focus on women's health. Henlius, a biopharmaceutical company based in China, specializes in the development of Denosumab biosimilars, including HLX14.

Major companies operating in the denosumab market report are Johnson & Johnson, F. Hoffmann-La Roche Ltd., Novartis International AG, Sanofi SA, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Asahi Kasei Corporation, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Daiichi Sankyo Company, Limited, Mylan N.V., Sandoz International GmbH, Daiichi Sankyo Company Limited, Aurobindo Pharma Limited, Cipla Limited, Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals PLC, Celltrion Inc., Amneal Pharmaceuticals Inc, Cadila Healthcare Limited, Lupin Limited, Biocon Limited, Torrent Pharmaceuticals Ltd., Jubilant Life Sciences Limited, Ajanta Pharma Limited

North America was the largest region in the denosumab market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the denosumab market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the denosumab market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The denosumab market consists of sales of calcium supplements and vitamin D supplements. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Denosumab Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on denosumab market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for denosumab ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The denosumab market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Classification: Prolia; Xgeva; Others
• 2) By Type: 60 mg; 120 mg
• 3) By End-Users: Hospitals; Homecare; Specialty Clinics; Ambulatory Surgical Centers
• Companies Mentioned: Johnson & Johnson; F. Hoffmann-La Roche Ltd.; Novartis International AG; Sanofi SA; GlaxoSmithKline plc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Denosumab Market Characteristics

3. Denosumab Market Trends And Strategies

4. Denosumab Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Denosumab Growth Analysis And Strategic Analysis Framework

• 5.1. Global Denosumab PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Denosumab Market Growth Rate Analysis
• 5.4. Global Denosumab Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Denosumab Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Denosumab Total Addressable Market (TAM)

6. Denosumab Market Segmentation

• 6.1. Global Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Prolia
• Xgeva
• Others
• 6.2. Global Denosumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 60 mg
• 120 mg
• 6.3. Global Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Homecare
• Specialty Clinics
• Ambulatory Surgical Centers

7. Denosumab Market Regional And Country Analysis

• 7.1. Global Denosumab Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Denosumab Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Denosumab Market

• 8.1. Asia-Pacific Denosumab Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Denosumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Denosumab Market

• 9.1. China Denosumab Market Overview
• 9.2. China Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Denosumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Denosumab Market

• 10.1. India Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Denosumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Denosumab Market

• 11.1. Japan Denosumab Market Overview
• 11.2. Japan Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Denosumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Denosumab Market

• 12.1. Australia Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Denosumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Denosumab Market

• 13.1. Indonesia Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Denosumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Denosumab Market

• 14.1. South Korea Denosumab Market Overview
• 14.2. South Korea Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Denosumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Denosumab Market

• 15.1. Western Europe Denosumab Market Overview
• 15.2. Western Europe Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Denosumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Denosumab Market

• 16.1. UK Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Denosumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Denosumab Market

• 17.1. Germany Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Denosumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Denosumab Market

• 18.1. France Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Denosumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Denosumab Market

• 19.1. Italy Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Denosumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Denosumab Market

• 20.1. Spain Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Denosumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Denosumab Market

• 21.1. Eastern Europe Denosumab Market Overview
• 21.2. Eastern Europe Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Denosumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Denosumab Market

• 22.1. Russia Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Denosumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Denosumab Market

• 23.1. North America Denosumab Market Overview
• 23.2. North America Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Denosumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Denosumab Market

• 24.1. USA Denosumab Market Overview
• 24.2. USA Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Denosumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Denosumab Market

• 25.1. Canada Denosumab Market Overview
• 25.2. Canada Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Denosumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Denosumab Market

• 26.1. South America Denosumab Market Overview
• 26.2. South America Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Denosumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Denosumab Market

• 27.1. Brazil Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Denosumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Denosumab Market

• 28.1. Middle East Denosumab Market Overview
• 28.2. Middle East Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Denosumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Denosumab Market

• 29.1. Africa Denosumab Market Overview
• 29.2. Africa Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Denosumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Denosumab Market Competitive Landscape And Company Profiles

• 30.1. Denosumab Market Competitive Landscape
• 30.2. Denosumab Market Company Profiles
  • 30.2.1. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Novartis International AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis

31. Denosumab Market Other Major And Innovative Companies

• 31.1. Eli Lilly and Company
• 31.2. Amgen Inc.
• 31.3. Asahi Kasei Corporation
• 31.4. Teva Pharmaceutical Industries Ltd.
• 31.5. Astellas Pharma Inc.
• 31.6. Daiichi Sankyo Company, Limited
• 31.7. Mylan N.V.
• 31.8. Sandoz International GmbH
• 31.9. Daiichi Sankyo Company Limited
• 31.10. Aurobindo Pharma Limited
• 31.11. Cipla Limited
• 31.12. Dr. Reddy's Laboratories Ltd.
• 31.13. Hikma Pharmaceuticals PLC
• 31.14. Celltrion Inc.
• 31.15. Amneal Pharmaceuticals Inc

32. Global Denosumab Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Denosumab Market

34. Recent Developments In The Denosumab Market

35. Denosumab Market High Potential Countries, Segments and Strategies

• 35.1 Denosumab Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Denosumab Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Denosumab Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer